Press Releases

October 20, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 5th International Virtual Conference on Cancer Research &

September 29, 2020 08:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation

September 23, 2020 08:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to

ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D.,

Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBM

-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. &

-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering

Data from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice June 11, 2020 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics,

-ITI Board adds significant oncology drug development and commercialization expertise to the Board- May 05, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage

-Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-

GOLDEN, Colo., April 14, 2020 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine being